Trial 16M-11-3

A Phase II Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Ann Mohrbacher, M.D.
Other Trial Staff: Lori Vergara, R.N., Ibrahim Syed, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.